Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05551299
Other study ID # CARP
Secondary ID 2022-500107-50-0
Status Recruiting
Phase Phase 4
First received
Last updated
Start date February 10, 2023
Est. completion date April 2028

Study information

Verified date February 2024
Source University of Leipzig
Contact Albrecht Hoffmeister, Prof.Dr.med.
Phone +49-341-97-12240
Email albrecht.hoffmeister@medizin.uni-leipzig.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Bile duct cancer is often diagnosed after curative options are no longer available. Stent therapy is used to keep the ducts open and can be combined with photodynamic therapy (PDT) to extend life expectancy. PDT requires an injection of photosensitizer after which light of a particular wavelength is applied endoscopically to kill the cancer cells. Drawbacks include not only high costs and poor availability, but foremost that patients have to avoid direct sunlight for a period of weeks. Radio frequency ablation (RFA) together with stent implantation constitutes an alternative by which the cancer cells are killed through heat, also applied endoscopically. The RFA technology is more widely available and easier to deploy. However, it has not been studied extensively and no randomized trials exist comparing the two methods. This trial will compare survival in patients with a particular bile duct cancer depending on whether they receive PDT or RFA. Moreover, data will be collected on side-effects and quality of life.


Description:

Klatskin tumours are a form of bile duct cancer. They are generally not diagnosed until quite late and a curative operation is rarely a possibility. Their anatomic location usually results in bile duct obstruction and the aim of therapy is thus to keep the ducts open. This is accomplished through endoscopic retrograde cholangiopancreatography (ERCP) by implanting stents. Stent therapy combined with photodynamic therapy (PDT) extends life expectancy. PDT requires an injection of photosensitizer that is absorbed primarily by the cancer cells. Light of a particular wavelength is then applied with ERCP to kill the cancer cells. Drawbacks include not only high costs and poor availability, but foremost that patients have to avoid direct sunlight for a period of weeks. Radio frequency ablation (RFA) together with stent implantation constitutes an alternative by which the cancer cells are killed through heat applied during ERCP. The RFA technology is more widely available and easier to deploy. However, it has not been studied extensively and no randomized trials exist comparing the two methods. This trial will compare survival in patients with Klatskin tumours depending on whether they receive PDT or RFA. Moreover, data will be collected on side-effects and quality of life.


Recruitment information / eligibility

Status Recruiting
Enrollment 258
Est. completion date April 2028
Est. primary completion date April 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Hilar cholangiocarcinoma (cytological or histological confirmation) 2. Surgery is not planned 3. Age = 18 years 4. Written informed consent Exclusion Criteria: 1. Tumour not accessible endoscopically 2. Known hypersensitivity to porphyrins or to any of the other ingredients of the photosensitizer chosen 3. Leukopenia (< 2000/mm3) 4. Thrombocytopenia (< 100,000 / mm³) 5. Severe, uncorrected coagulopathy (at the discretion of the physician) 6. Suspected erosion of major blood vessels, because of the risk of life-threatening mass haemorrhage exists 7. Porphyria (clinician's assessment) or other light-exacerbated diseases 8. Severely impaired liver and or kidney function (at the discretion of the physician) 9. Bedridden for more than 50% of the time (similar to ECOG (Eastern Cooperative Oncology Group) grade 3) 10. Planned surgical procedure within the next 30 days 11. Concurrent eye disease that will require a slit lamp examination within the next 30 days 12. Prior radiotherapy within the last four weeks 13. Previous PDT or RFA 14. Planned liver transplantation 15. Fertile women (within two years of their last menstruation) without appropriate contraceptive measures (implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy) while participating in the trial (participants using a hormone-based method have to be informed of possible effects of the trial medication on contraception) 16. Participation in other interventional trials 17. Patients under legal supervision or guardianship 18. Pregnant or nursing women

Study Design


Intervention

Drug:
Photosensitizer
A photosensitizer, which is absorbed preferentially by tumour cells, is administered 24 - 48 hours prior to PDT. Light of a particular wavelength is then applied during endoscopic retrograde cholangiopancreatography (ERCP) to kill primarily cancer cells locally within the stenosis. Immediately after PDT treatment, new stents are inserted into all treated segments if needed.
Procedure:
Radiofrequency ablation (RFA)
RFA is also carried out as part of an ERCP. The RFA-probe is placed within the tumour stenosis and electrical current is applied. New stents are inserted into all treated segments if needed.

Locations

Country Name City State
Germany Uniklinik RWTH Aachen, Medizinische Klinik III Aachen
Germany Universitätsklinikum Augsburg; III. Med. Klinik Augsburg
Germany Vivantes Netzwerk für Gesundheit GmbH, Klinikum Friedrichshain, Innere Medizin/Gastroenterologie Berlin
Germany Universitatsklinikum Bonn, Medizinische Klinik und Poliklinik I Bonn
Germany Universitätsklinikum Frankfurt, Medizinische Klinik 1 Frankfurt
Germany Universitätsklinikum Freiburg, Medizinische Klinik II, Abteilung Gastroenterologie, Hepatologie, Endokrinologie & lnfektiologie Freiburg
Germany Universitätsmedizin Greifswald Klinik für Innere Medizin A Greifswald
Germany Site: Martin-Luther-Universitat Halle-Wittenberg, Universitätsklinik und Poliklinik für Innere Medizin I Halle
Germany Klinikum Hanau; Klinik für Gastroenterologie, Diabetologie und Infektiologie Hanau
Germany KRH Klinikum Siloah, Klinik für Gastroenterologie Hannover
Germany Klinikum St. Georg gGmbH; Klinik für Gastroenterologie, Hepatologie, Diabetologie und Endokrinologie Leipzig
Germany University Hospital of Leipzig, Department of Gastroenterology Leipzig
Germany RKH Kliniken Ludwigsburg- Bietigheim gGmbH, Klinik für Innere Medizin, Gastroenterologie, Hämato-Onkologie, Diabetologie und Infektiologie Ludwigsburg
Germany Universitätsmedizin Mannheim, II. Medizinische Klinik Mannheim
Germany Universitätsklinikum Gießen und Marburg GmbH (UKGM); Klinik für Innere Medizin mit den Schwerpunkten Gastroenterologie, Endokrinologie, Stoffwechsel und klinische Infektiologie Marburg
Germany Klinikum der LMU München, Medizinische Klinik II, Campus Großhadern München
Germany Universitlitsklinikum Munster Medizinische Klinik B (Gastroenterologie, Hepatologie, Endokrinologie, Klinische lnfektiologie) Münster
Germany Klinikum Nürnberg Nord; Gastroenterologie/ Endokrinologie Nürnberg
Germany Robert-Bosch-Krankenhaus (RBK) Stuttgart; Gastroenterologie, Hepatologie und Endokrinologie Stuttgart
Germany Universitätsklinikum Tübingen, Medizinische Klinik I Tübingen

Sponsors (2)

Lead Sponsor Collaborator
University of Leipzig Zentrum für Klinische Studien Leipzig

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival Hazard ratio from a Cox regression model will be used to compare randomization arms. Covariates will be stratification variables, classification of local inoperability, use of prophylactic antibiotics, Bismuth type and time between diagnosis and beginning RFA/PDT. through study completion, an average of 1 year
Secondary Overall survival (complementary perspective: median survival time) Estimates of the difference in median survival time between the groups will be based on the method of Chen and Zhang (PMID: 26983640). through study completion, an average of 1 year
Secondary Overall survival (complementary perspective: two-year overall survival) Kaplan-Meier estimates will be used. up to two years
Secondary Overall survival (complementary perspective: restricted mean survival on a time horizon of two-years) Kaplan-Meier estimates will be used (see e.g. PMID: 15690989) through study completion, an average of 1 year
Secondary Days alive and out of hospital up to two years This constitutes a basic and easy to understand measure of quality of life. Only in-hospital stays will be included in this endpoint and the day of arrival and dismissal will each be counted. The source of data will be the hospital records, epicrisis and patient disclosure. up to two years
Secondary Quality of Life (QoL) measured using QLQ-C30 at various points in time after randomization (V2 (14 days), V3 (ca. 3 months), as a function of time after 6 months, adjusting for the baseline value) Prolonging life is especially worthwhile if QoL is sufficiently good. The established cancer-specific Core Quality of Life questionnaire QLQ-C30 from the EORTC (European Organisation for Research will be used. Shortly after the index therapy (V2, V3), the difference between arms will be assessed. The requirement to stay indoors may affect QoL. At later points in time, a description per arm is of interest and will be based on a weighted mean of all available questionnaires, weighting according to calendar time. through study completion, an average of 1 year
Secondary Quality of Life (QoL) measured using FACT-Hep at various points in time after randomization (V2 (14 days), V3 (ca. 3 months), as a function of time after 6 months, adjusting for the baseline value) Prolonging life is especially worthwhile if QoL is sufficiently good. The Functional Assessment of Cancer Therapy - Hepatobiliary (FACT-Hep) questionnaire, containing the hepatobiliary-specific cancer subscale, will be used as a second instrument for assessing QoL. Shortly after the index therapy (V2, V3), the difference between arms will be assessed. The requirement to stay indoors may affect QoL. At later points in time, a description per arm is of interest and will be based on a weighted mean of all available questionnaires, weighting according to calendar time. through study completion, an average of 1 year
Secondary Quality-adjusted life years (QALYs) Using QALYs, a weighted measure of survival will be compared between RFA and PDT that takes QoL into account. The details will be provided in a Statistical Analysis Plan. through study completion, an average of 1 year
Secondary Stent patency based on clinician's assessment (e.g. cholangitis, cholestasis, ultrasound) Stent patency provides one measure of the burden of the disease and efficacy of the treatment. Mean time to stent closure/replacement/death after last stent replacement will be analysed. through study completion, an average of 1 year
Secondary Laboratory parameter (leucocytes) Changes in laboratory parameters after index treatment (V3) and as a function of time will be analysed and compared between randomization arms. through study completion, an average of 1 year
Secondary Laboratory parameter (haematocrit) Changes in laboratory parameters after index treatment (V3) and as a function of time will be analysed and compared between randomization arms. through study completion, an average of 1 year
Secondary Laboratory parameter (haemoglobin) Changes in laboratory parameters after index treatment (V3) and as a function of time will be analysed and compared between randomization arms. through study completion, an average of 1 year
Secondary Laboratory parameter (bilirubin) Changes in laboratory parameters after index treatment (V3) and as a function of time will be analysed and compared between randomization arms. through study completion, an average of 1 year
Secondary Laboratory parameter (albumin) Changes in laboratory parameters after index treatment (V3) and as a function of time will be analysed and compared between randomization arms. through study completion, an average of 1 year
Secondary Laboratory parameter (CA 19-9) Changes in laboratory parameters after index treatment (V3) and as a function of time will be analysed and compared between randomization arms. through study completion, an average of 1 year
Secondary Laboratory parameter (CRP) Changes in laboratory parameters after index treatment (V3) and as a function of time will be analysed and compared between randomization arms. through study completion, an average of 1 year
Secondary Laboratory parameter (ALT) Changes in laboratory parameters after index treatment (V3) and as a function of time will be analysed and compared between randomization arms. through study completion, an average of 1 year
Secondary Laboratory parameter (GGT) Changes in laboratory parameters after index treatment (V3) and as a function of time will be analysed and compared between randomization arms. through study completion, an average of 1 year
Secondary Pruritus as reported by patients on a scale from 0 ("no itching") to 10 ("worst imaginable itching"). Pruritus will be analysed as a function of time. through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05678218 - Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
Enrolling by invitation NCT01715402 - Optimization of Health Expenditure in Liver Surgery N/A
Completed NCT03320980 - RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma N/A
Completed NCT00721175 - Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar Cholangiocarcinoma Phase 4
Recruiting NCT05626127 - MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma
Terminated NCT02082522 - Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) Phase 3
Active, not recruiting NCT05239169 - Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer Phase 2
Recruiting NCT02178280 - Safety Study of Liver Transplantation for Hilar Cholangiocarcinoma Phase 1/Phase 2
Terminated NCT02955771 - Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma Phase 2
Recruiting NCT03132649 - Impact of Three-dimensional Visualization on Operation Strategy and Complications for Hilar Cholangiocarcinoma
Recruiting NCT04561453 - Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer
Recruiting NCT02108145 - Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma Phase 2/Phase 3
Enrolling by invitation NCT03739164 - Tampa Associating Microwave Liver Ablation With Portal Vein Ligation for Staged Hepatectomy (TAMLAPS)
Recruiting NCT02801500 - Superior Bilioenteric Anastomosis by Magnetic Compressive Technique N/A
Recruiting NCT01549795 - Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy N/A
Recruiting NCT06106750 - Endoscopic Scissors Cutting Nasobiliary Duct VS Bilateral Plastic Stent N/A
Active, not recruiting NCT02042443 - Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Phase 2
Completed NCT01093222 - Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Phase 2
Enrolling by invitation NCT04779788 - I-125 Seeds Loaded Stent Insertion for Inoperable Hilar Cholangiocarcinoma N/A
Completed NCT04611100 - Efficacy of Intraductal Radiofrequency Ablation in Combination With Metallic Biliary Stenting in Advanced Hilar Cholangiocarcinoma N/A